Kolexia
Eberst Lauriane Oncologie médicale
Eberst Lauriane
Oncologie médicale
Hus Site Icans
Strasbourg, France
101 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Tumeurs du sein Métastase tumorale Carcinome épithélial de l'ovaire Tumeurs de l'endomètre Carcinomes Tumeurs colorectales Récidive tumorale locale Tumeurs du cerveau

Collaborateurs

Voir plus
Cassier Philippe
Cassier Philippe
Centre Léon-Bérard, Lyon, France
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France
Perol David
Perol David
Centre Léon-Bérard, Lyon, France
Tredan Olivier
Tredan Olivier
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
AstraZeneca
12 collaboration(s)
Dernière en 2023
GSK
7 collaboration(s)
Dernière en 2023
KEPHREN
4 collaboration(s)
Dernière en 2023
MSD
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
PROFILER: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Essai Clinique (Centre Léon-Bérard)   01 mars 2024
DOMENICA: Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Essai Clinique (GSK)   28 février 2024
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas: A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Essai Clinique (Constellation Pharmaceuticals)   15 février 2024
ALEPRO: A Phase II, Open-label, Multicenter Study of Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
Essai Clinique (Lilly)   09 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE): A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Essai Clinique (PMV Pharmaceuticals, Inc)   07 février 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Science translational medicine   24 janvier 2024
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023
PembroSCCOHT: Multicentric Non-randomized Phase II of Pembrolizumab in Combination With Etoposide-cisplatin-based Chemotherapy in First-line Small Cell Ovarian Carcinoma of Hypercalcemic Type
Essai Clinique (Merck & Co.)   17 novembre 2023
Phase III positive pour le pembrolizumab dans le cancer du col localement avancé
Edimark   21 octobre 2023